REGENERON PHARMACEUTICALS, INC.

REGNLast close 735.20 USD · Oct 2, 2026

Machine signal

Active cluster sell — 4 distinct insiders, $3.4M, window ends Sep 3, 2026.

Insider trading at REGENERON PHARMACEUTICALS, INC.

Transactions on record: 9,450; since Aug 14, 2003

Insider buys: 551; $2.5B

Insider sells: 4,193; $14.7B

Active insiders · 12 months: 19; last filing Sep 3, 2026

Figures computed from official regulatory filings — .

Company financials

Revenue (TTM): 15.5B

EBITDA: 4.7B

EPS (TTM): 40.44

Profit margin: 27.9%

Return on equity: 14.0%

Revenue growth (YoY): 16.7%

P/E ratio: 18.18

Forward P/E: 14.51

Price / sales: 4.87

EV / EBITDA: 13.07

Price / book: 2.6

Dividend yield: 0.5%

52-week range: 538.24–859.34

Analysttarget 853.19 USD (+16%) · consensus 4.15/5 · 18 buy · 8 hold · 1 sell

Ownershipinsiders 2.09% · institutions 93.54% · short 2.6% of float

In USD · as of Oct 5, 2026

Insiders on record at REGENERON PHARMACEUTICALS, INC.

Show all 40 insiders on record

About the company

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Insider	Filed	Type	Qty	Price	Value · USD	Signals	Src	Details
McCourt Marion	Sep 3, 2026	Sell	-1,131	857.39 USD	$969.7K		SEC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Listing on recordSecurity status from the latest source received, not a guarantee of tradability.

Former names

Periods recorded in the consulted sources. These do not certify the legal dates of name changes.

REGENERON PHARMACEUTICALS INCJul 26, 1995 / Jun 19, 2019

REGENERON PHARMACEUTICALS, INC.

Insider trading at REGENERON PHARMACEUTICALS, INC.

Company financials

Insiders on record at REGENERON PHARMACEUTICALS, INC.

REGENERON PHARMACEUTICALS, INC.

Insider trading at REGENERON PHARMACEUTICALS, INC.

Company financials

Insiders on record at REGENERON PHARMACEUTICALS, INC.

Insider transaction history at REGENERON PHARMACEUTICALS, INC.

About the company

Insider transaction history at REGENERON PHARMACEUTICALS, INC.